Update: February 29, 2020
Aclaris Exists Hair Loss Business
The rumors are unfortunately true. Several days ago, I contacted Aclaris Therapeutics’ Head of Corporate Strategy Mr. Michael Tung. I asked him for any update on their androgenetic alopecia (AGA) JAK inhibitor product. His short and succinct response:
“We exited all of that unfort”.
I am disappointed, but was expecting this bad news. Their pipeline page no longer even shows any products to target AGA or Alopeica Areata (AA).
Sorry to reader “nasa_rs”. But not a big surprise after the past year of limited information releases by Aclaris regarding their hair loss product.
March 18, 2019
I used to cover Aclaris Therapeutics and its topical JAK inhibitor product for androgenetic alopecia fairly regularly. However, there have been very few significant recent updates.
Today morning, Aclaris released a summary of its FY 2018 results. The most relevant part for us concerns the ATI-502 topical product for androgenetic alopecia. They also seem to name this product as AGA-201 and ATI-50002.
Per the latest news, Phase 2 open-label clinical trials for ATI-502 (a topical JAK1/3 inhibitor) involve 31 patients with AGA. Interim 6-month data are expected in the second quarter of 2019, while comprehensive 12-month data will be realized in the second half of 2019.
So by the end of this year, we should finally have at least some idea on whether JAK inhibitors can at least somewhat help patients with AGA (aka male pattern hair loss). The trials will measure both safety and efficacy.
We already know beyond a doubt that JAK inhibitors significantly help people with the less common alopecia areata (AA). As well as its various related forms (alopecia totalis and alopecia universalis).
The post An Overdue Aclaris Update appeared first on Hair Loss Cure 2020.